UNSPSC 51314359: Desloratadine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314359 Desloratadine/pseudoephedrine is a Commodity code that in practice captures state and local procurement of pharmaceutical products and over-the-counter medications, though recent solicitation activity under this code shows minimal alignment with the specific drug name and instead reflects broader generic and OTC product purchasing. State and local health departments, county health systems, and cooperative purchasing alliances solicit under this code to fill their pharmaceutical inventories and support community health programs. The work involves sourcing FDA-compliant generic pharmaceuticals, OTC products, naloxone, and drug deactivation systems through competitive bidding, with vendors required to maintain cGMP certification, DSCSA compliance, appropriate insurance coverage, and E-Verify authorization. Contracts typically run two years with optional renewals and include quarterly or routine delivery to specified facilities, with pricing structured around fixed costs, net pricing formats, or WAC-minus discounts depending on the procurement mechanism.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023, through the county's e-Procurement Portal with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage procurement planning for direct contracting with pharmaceutical manufacturers outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products effective July 1, 2026, requiring vendors to supply through AmerisourceBergen, Cardinal Health, or Morris & Dickson with responses due March 26, 2026, and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on compliance and EDI capability.